Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Presym Inc.

This article was originally published in Start Up

Executive Summary

Although roughly 80% of all heart disease is attributable to mechanical defects, the medical community relies on ultrasound imaging and other electrical/impedance methods to diagnose heart diseases. While these techniques are valuable for detecting arrhythmias and other electrical disturbances, they are unable to identify biomechanical issues that may develop into serious problems. Presym Inc. is working on a new noninvasive device that uses the trachea as a point of measurement to record all mechanical features of the heart and thus detect diseases before symptoms occur.

You may also be interested in...



Start-Up Previews (03/2010)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Transdermal Drug Delivery: More Than Skin Deep, features profiles of AllTranz, Ocelus, Quinnova and Syntropharma. Plus these Start-Ups Across Health Care: Apnex Medical, Cellular Dynamics, Helix Therapeutics, Presym and Vatrix Medical.

EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions

It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel